Clinical trial
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)
NCT04035668 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 12, 2019
- Completion date
- November 23, 2021
- Enrollment
- 73 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
sjögren syndrome